[Systemic lupus erythematosus--activity and outcome].
Both clinically and scientifically, the variable organ manifestations of systemic lupus erythematosus (SLE) pose a particular challenge to rheumatologists. Validated scores for disease activity (BILAG, ECLAM, SIS, SLAM, SLEDAI), damage (SLICC/ACR damage index) and health-related quality of life (MOS SF-36) have been successfully used for years. New therapies, however, need to show improvement on outcome parameters for defined organ systems--and these are mostly ill-defined. For proliferative lupus nephritis, well designed studies have been available for years. However, these use very severe outcome parameters (renal failure, death), and therefore take at least 5 years for definitive results. Of the surrogate markers which were devised, none has proven reliable for determining outcome. The combination of shorter studies for defining hopeful strategies followed by long definitive studies, appears to be the best option at present.
Aringer
M
M
Klinische Abt. für Rheumatologie, Universitätsklinik für Innere Medizin III, Wien. martin.aringer@meduniwien.ac.at
Smolen
J
J
D018771:Arthralgia / Q000175:diagnosis* / Q000517:prevention & control*; D018450:Disease Progression; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000145:classification / Q000175:diagnosis* / Q000628:therapy*; D017063:Outcome Assessment, Health Care / Q000379:methods*; D010147:Pain Measurement / Q000379:methods*; D010818:Practice Patterns, Physicians'; D011379:Prognosis; D016896:Treatment Outcome